Trial reportBritish journal of cancer2009
Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.
Trial report in British journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04158544 (Immune Monitoring During Systemic Therapy of Metastatic Malignant Melanoma), which is not on this map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immune Monitoring During Systemic Therapy of Metastatic Malignant Melanoma
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.
- The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis.PloS one · 2012Pooled it
- Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2014Trial
- The Value of Cell-Free Circulating DNA Profiling in Patients with Skin Diseases.Methods in molecular biology (Clifton, N.J.) · 2023Review
- Metabolism heterogeneity in melanoma fuels deactivation of immunotherapy: Predict before protect.Frontiers in oncology · 2022Review
- Evaluating the Diagnostic Potentials of Circulating Tumor DNA against Melanoma: A Systematic Review and Meta-Analysis.Journal of oncology · 2022Article
- Article
- Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis.Journal of oncology · 2021Article
- Adaptive redox homeostasis in cutaneous melanoma.Redox biology · 2020Review
- The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape.Frontiers in molecular biosciences · 2020Review
- Review
- Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications.BioMed research international · 2017Review
- Exploring the impact ofOncology letters · 2016Article
- Somatic mutations in histiocytic sarcoma identified by next generation sequencing.Virchows Archiv : an international journal of pathology · 2016Article
- Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma.The Journal of molecular diagnostics : JMD · 2016Article
- Tumor Heterogeneity and Therapeutic Resistance.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2016Review
- cfDNA analysis from blood in melanoma.Annals of translational medicine · 2015Review
- Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2.Drugs · 2015Review
- SNPase-ARMS qPCR: Ultrasensitive Mutation-Based Detection of Cell-Free Tumor DNA in Melanoma Patients.PloS one · 2015Article
- Article
- DNA hybridization detection with 100 zM sensitivity using piezoelectric plate sensors with an improved noise-reduction algorithm.The Analyst · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThis study investigated the potential clinical utility of circulating free DNA (cfDNA) as a source of BRAF mutation detection in patients enrolled into a phase II study of AZD6244, a specific MEK1/2 inhibitor, in patients with advanced melanoma.
methodsBRAF mutations were detected using Amplification Refractory Mutation System allele-specific PCR. BRAF mutation status was assessed in serum-derived cfDNA from 126 patients enrolled into the study and from 94 matched tumour samples.
resultsOf 94 tumour samples, 45 (47.9%) were found to be BRAF mutation positive (BRAF+). Serum-derived cfDNA was BRAF+ in 33 of 126 (26.2%) samples, including in five samples for which tumour data were unavailable. Of BRAF+ tumours, 25 of 45 (55.6%) were BRAF+ in cfDNA. In three cases in which the tumour was negative, cfDNA was BRAF+. Progression-free survival (PFS) of patients with BRAF+ tumour and cfDNA was not significantly different compared with tumour BRAF+ but cfDNA BRAF-negative patients, indicating that cfDNA BRAF detection is not associated with poorer prognosis on PFS in stage III/IV advanced melanoma.
conclusionsThese data demonstrate the feasibility of BRAF mutation detection in cfDNA of patients with advanced melanoma. Future studies should aim to incorporate BRAF mutation testing in cfDNA to further validate this biomarker for patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.